首页> 美国卫生研究院文献>Cancer Research and Treatment : Official Journal of Korean Cancer Association >Delayed Terminal Ileal Perforation in a Relapsed/Refractory B-Cell Lymphoma Patient with Rapid Remission Following Chimeric Antigen Receptor T-Cell Therapy
【2h】

Delayed Terminal Ileal Perforation in a Relapsed/Refractory B-Cell Lymphoma Patient with Rapid Remission Following Chimeric Antigen Receptor T-Cell Therapy

机译:嵌合抗原受体T细胞治疗后复发快速/难治性B细胞淋巴瘤患者的晚期回肠穿孔延迟。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Chimeric antigen receptor T-cell strategy targeting CD19 (CART19) has prominent anti-tumor effect for relapsed/refractory B-cell lymphomas. CART19-associated complications have been gradually recognized, however, late-onset complications have not been extensively studied. Herein, for the first time we report a diffuse large B-cell lymphoma patient with terminal ileum involvement obtained rapid remission and developed spontaneous terminal ileal perforation 38 days following CART19 infusion. The late-onset perforation reminds us that, for the safety of CART treatment, more cautions are warranted for the management of delayed GI complications.
机译:靶向CD19的嵌合抗原受体T细胞策略(CART19)对复发/难治性B细胞淋巴瘤具有显着的抗肿瘤作用。与CART19相关的并发症已被逐渐认识,但是,迟发性并发症尚未得到广泛研究。在此,我们首次报道了CART19输注后38天,患有末端回肠受累的弥漫性大B细胞淋巴瘤患者获得了快速缓解并发展为自发性末端回肠穿孔。迟发性穿孔提醒我们,为了CART治疗的安全性,对于延迟性GI并发症的处理应多加注意。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号